-

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Travere Therapeutics will participate at upcoming investor conferences.

Share

Guggenheim's 2nd Annual Healthcare Innovation Conference
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET

Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025

TD Cowen Immunology & Inflammation Summit
Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET

Jefferies Global Healthcare Conference
Presenting on Tuesday, November 18, 2025, at 3:00 p.m. GMT (10:00 a.m. ET)

8th Annual Evercore Healthcare Conference
Presenting on Tuesday, December 2, 2025, at 10:50 a.m. ET

Piper Sandler 37th Annual Healthcare Conference
Wednesday, December 3, 2025

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contacts

Investors:
888-969-7879
IR@travere.com

Media:
888-969-7879
mediarelations@travere.com

Travere Therapeutics, Inc.

NASDAQ:TVTX
Details
Headquarters: San Diego, CA
CEO: Eric Dube, Ph.D.
Employees: 385
Organization: PUB

Release Versions

Contacts

Investors:
888-969-7879
IR@travere.com

Media:
888-969-7879
mediarelations@travere.com

Social Media Profiles
More News From Travere Therapeutics, Inc.

Travere Therapeutics to Report Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere’s website at https://ir.travere.com/events-and-presentations....

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 23,600 shares of its common stock. These inducement s...

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and be named executive vice president, head of research and development and CMO....
Back to Newsroom